Increase of number of shares and votes in Vicore Pharma
As previously announced, the Company’s board of directors resolved on a set-off issue of 87,686 shares at a subscription price of SEK 34.21 per share on June 17, 2022. The set-off issue was carried out as part of a milestone payment to the company’s collaboration partners Emeriti Bio AB and HaLaCore Pharma AB, for the start of a phase 1 trial with C106.
As of today, the total number of registered and outstanding shares and votes of Vicore Pharma amounts to 71,847,979. Furthermore, the registered share capital amounts to approximately SEK 35,923,989.15.
For further information, please contact:
Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on June 30, 2022, at 09:00 CEST.